1. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia
    Islem Ben Hassine et al, 2017, Cancer Chemother Pharmacol CrossRef
  2. Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
    Claudia Neul et al, 2016, Trends in Pharmacological Sciences CrossRef
  3. Current trends in molecular diagnostics of chronic myeloid leukemia
    Raquel Vinhas et al, 2017, Leukemia & Lymphoma CrossRef
  4. BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report
    Ana P Azevedo et al, 2017, Clinical Medicine Insights: Oncology CrossRef
  5. null
    Ana Azevedo et al, 2019 CrossRef
  6. OCT1 and imatinib transport in CML: is it clinically relevant?
    D B Watkins et al, 2015, Leukemia CrossRef
  7. Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug–drug interactions
    C Arimany-Nardi et al, 2015, Pharmacogenomics J CrossRef
  8. Drug Resistance-Related Competing Interactions of lncRNA and mRNA across 19 Cancer Types
    Haizhou Liu et al, 2019, Molecular Therapy - Nucleic Acids CrossRef
  9. null
    Marta Gromicho et al, 2016 CrossRef
  10. null
    Bruno Costa Gomes et al, 2016 CrossRef
  11. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
    Luciene Terezina de Lima et al, 2014, Med Oncol CrossRef
  12. MDR1gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis
    Bailing Zu et al, 2014, Pharmacogenomics CrossRef
  13. Gene expression profiling for targeted cancer treatment
    Anton Yuryev, 2015, Expert Opinion on Drug Discovery CrossRef
  14. Identifying and Validating a Combined mRNA and MicroRNA Signature in Response to Imatinib Treatment in a Chronic Myeloid Leukemia Cell Line
    Steven Bhutra et al, 2014, PLoS ONE CrossRef
  15. OCT-1,ABCB1, andABCG2Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
    Yeo-Kyeoung Kim et al, 2014, Chonnam Med J CrossRef
  16. Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia
    Gloria Ravegnini et al, 2016, Expert Opinion on Drug Metabolism & Toxicology CrossRef
  17. Trough concentration andABCG2polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis
    Zhi-Ping Jiang et al, 2017, Pharmacogenomics CrossRef
  18. The multi-factorial nature of clinical multidrug resistance in cancer
    Yehuda G. Assaraf et al, 2019, Drug Resistance Updates CrossRef
  19. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
    Monika Jaruskova et al, 2017, J Exp Clin Cancer Res CrossRef
  20. The human organic cation transporter OCT1 and its role as a target for drug responses.
    Nicolas Brosseau et al, 2019, Drug Metab Rev CrossRef
  21. Organic Cation Transporters in Health and Disease
    Hermann Koepsell et al, 2020, Pharmacol Rev CrossRef
  22. ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance
    Bruno C. Gomes et al, 2020, IJMS CrossRef
  23. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis
    N Louati et al, 2021, J Oncol Pharm Pract CrossRef
  24. Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia
    Fatemeh Mohammadi et al, 2021 CrossRef
  25. OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment
    Betul Bozkurt Bulakcı et al, 2022, Indian J Hematol Blood Transfus CrossRef
  26. QSAR modeling and molecular docking studies of 2-oxo-1, 2-dihydroquinoline-4- carboxylic acid derivatives as p-glycoprotein inhibitors for combating cancer multidrug resistance
    M. Lahyaoui et al, 2023, Heliyon CrossRef